{"ticker": {"uuid": "7f999094-0ff4-4a56-bfc7-e7cb33c74097", "symbol": "PMN", "name": "ProMIS Neurosciences Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)", "summary": "Guggenheim reiterated its \"Buy\" rating for ProMIS Neurosciences (PMN) with a $35.00 price target, following a previous \"Buy\" rating from Roth MKM. Despite a quarterly GAAP net loss of $8.24 million, corporate insider sentiment is positive, with increased insider buying, including", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3292705/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T11:41:29", "published_display": "15 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS reports PMN310 oligomer reduction at 29 days", "summary": "ProMIS Neurosciences reported that its drug candidate PMN310 demonstrated dose-dependent reductions in detectable amyloid-beta oligomers within cerebrospinal fluid three and 29 days after a single dose. This finding provides an exploratory signal that PMN310 reached and engaged i", "url": "https://grafa.com/en/news/united-states/promis-pmn310-amyloid-oligomer-reduction-29-days", "source_name": "grafa.com", "published_at": "2026-07-14T11:01:00", "published_display": "14 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in Amyloid-Beta Oligomers", "summary": "ProMIS Neurosciences Inc. (PMN) announced promising results from its Phase 1a trial for the Alzheimer's drug candidate PMN310, showing a dose-dependent reduction in amyloid-beta oligomers. Despite strong financial health with no debt, the company faces profitability challenges, r", "url": "https://www.gurufocus.com/news/8957080/promis-neurosciences-pmn-reports-dosedependent-reduction-in-amyloidbeta-oligomers", "source_name": "GuruFocus", "published_at": "2026-07-14T10:40:52", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Reports Dose-Dependent Reduction of Amyloid-Beta Oligomers for PMN310 in Healthy Volunteers", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPc2haeVBieEdKTTZCaXpodnA2QnFValNfWDB4NlIwTlFMemJuRWNjbWlhSnZ6UkRjSlZScGg1M2puZy1BM1FJNmluZHc0MFg3alBtRFRVU3NOdXduN2h2RHA3VmRvazVSRU84cFp2UVZ2enptVlFQNHRIMldMQTRDMm1BemZNcWV3N1RnNjdLQnhhcVpURjVDanM3X28yWkd6eWhKdlBST1BNV2ZrNFZKZmxDSWdXVHQxWTBpUGVGZjBMcVNsZDlfbENYT1c5YlpmdUhJcGczVS1xZDJ5T3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T06:40:00+00:00", "published_display": "14 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026", "summary": "ProMIS Neurosciences announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer's drug candidate, PMN310, at AAIC 2026. The findings from a Phase 1a trial showed a reduction in oligomers in healthy volunteers' cerebrospinal fluid, indica", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326583/0/en/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-target-engagement-by-pmn310-at-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T06:40:04", "published_display": "14 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid", "summary": "ProMIS Neurosciences announced that its Alzheimer's drug candidate, PMN310, demonstrated a dose-dependent reduction of amyloid-beta oligomers (A\u03b2O) in cerebrospinal fluid after a single dose in healthy volunteers. This finding, presented at AAIC 2026, represents a significant mil", "url": "https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-reports-first-human-evidence-of-amyloid-beta-4yt28payuim6.html", "source_name": "Stock Titan", "published_at": "2026-07-14T06:40:04", "published_display": "14 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ProMIS Neurosciences Inc. Financial Statements \u2013 NASDAQ:PMN", "summary": "This page provides financial statement information for ProMIS Neurosciences Inc. (NASDAQ:PMN). Key facts like market capitalization, dividend yield, and P/E ratio are currently unavailable, and the company has no history of paying dividends. ProMIS Neurosciences Inc. focuses on d", "url": "https://www.tradingview.com/symbols/PMN/financials-overview/", "source_name": "TradingView", "published_at": "2026-07-10T04:10:07", "published_display": "10 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates ProMIS Neurosciences at Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cantor-fitzgerald-initiates-promis-neurosciences-100223010.html", "source_name": "MT Newswires", "published_at": "2026-06-30T10:02:23+00:00", "published_display": "30 Jun 2026 10:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbU42Z0xNV2pXQ0pXZEtJNWp6Mk85Nm0yQ2g4d3pCREdITkNLY0RTVVF6LUFUN1FydGcwb2xGai1FYXBycUZuZ3BaM0dBZXV1bEVtQVZoOU1iekVBRXRuZVNxRTBfMkxxNjEwWWtlb1NvTzcxbEk2ZGxLOXVTa0JndlJldm5oMTZVZmhNQzE4R0RYY3VGWExiUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "The article \"Price to sales forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN\" from TradingView appears to be a stub or a section of a larger financial data page for ProMIS Neurosciences Inc. (PMN). It focuses on the \"Price to sales forward\" metric, although no specific value is ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:34", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "This article provides a brief mention of the \"Enterprise value to revenue forward\" metric for ProMIS Neurosciences Inc. (NASDAQ:PMN). It appears to be a financial data point presented on TradingView, likely indicating a valuation ratio for the company. The content itself is very ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:12:10", "published_display": "26 Jun 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN)", "summary": "This article provides an overview of ProMIS Neurosciences Inc. (NASDAQ:PMN) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial actuals and estimates for earnings and revenue, notes the company's next earn", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:10", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "This article displays the \"Price to earnings forward\" metric for ProMIS Neurosciences Inc. (NASDAQ: PMN) on the TradingView platform. The content primarily features navigation elements and data source attributions, with the core financial data point itself being the main focus fo", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:11:11", "published_display": "25 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18", "summary": "HC Wainwright & Co. has reiterated its \"Buy\" rating for ProMIS Neurosciences (PMN), maintaining a price target of $18.00. While the biotech company, which focuses on neurodegenerative disease therapies, has a strong financial balance sheet (rated 9/10), its GF Score of 32/100 sug", "url": "https://www.gurufocus.com/news/8929551/pmn-reiterated-by-hc-wainwright-co-price-target-maintained-at-18", "source_name": "GuruFocus", "published_at": "2026-06-24T12:40:46", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18", "summary": "H.C. Wainwright has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained its target price at $18. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72040789/hc-wainwright-maintains-promis-neurosciences-pmnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T07:41:15", "published_display": "24 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy", "summary": "H.C. Wainwright has reiterated its Buy rating and $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN), noting the stock's current value of $10.69 represents a significant upside to the target. The firm highlighted ProMIS Neurosciences' plans to develop a subcutaneous formul", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-promis-neurosciences-stock-rating-at-buy-93CH-4757907", "source_name": "Investing.com", "published_at": "2026-06-23T19:39:43", "published_display": "23 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ProMIS Neurosciences Inc (PMN), detailing its current price momentum score, support and resistance levels, and an evaluation based on various technical indicators and moving averages. According to the analysis, PMN is currently suitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/technical", "source_name": "TradingKey", "published_at": "2026-06-19T00:09:50", "published_display": "19 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ProMIS Neurosciences Inc (PMN), detailing its business segments, regional revenue, and profit contribution. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue data availab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:33", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of ProMIS Neurosciences Inc (PMN), listing major shareholders and their proportions, as well as a breakdown by shareholder type. It also provides institutional shareholding data from Q1 2023 to Q1 2026, showing changes in the number ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:33", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ProMIS Neurosciences Inc (PMN), highlighting its current earnings forecast score of 8.40 and an average price target of $112.50 from 5 analysts, with most recommending a \"Buy\" trend. It details the company's recent EPS performance, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:08", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ProMIS Neurosciences Inc (PMN), noting its current valuation score of 6.70 within the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio, indicating a loss, and states that relevant data for P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T23:10:18", "published_display": "16 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-promis-135502622.html", "source_name": "Zacks", "published_at": "2026-06-12T13:55:02+00:00", "published_display": "12 Jun 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTEZnWmR3cXhHMjRyckJ5S3BpbkhSZFEtcHpLbTE5VGJrZEZJc05aaDM4SG5FRWhWS0xtbEM4cS03LWZHcDV1T1dwV1RFUGFYSTVkZjZLby1YMVp5elhBOTRfSENsUk1Pam5wZUtyRmNDLVRZT3F4N0pwVy1DWTRsbk8tc3I2UEhhbzdra3JFZmpzdGRFVnZibnNOOERZUU1zTGpJ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and an $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN). The company's stock is currently trading at $9.71, and InvestingPro analysis suggests it is undervalued. ProMIS Neurosciences is nearing key milestones for its Phase 1b t", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-buy-on-promis-neurosciences-stock-93CH-4681696", "source_name": "Investing.com Canada", "published_at": "2026-06-09T11:39:13", "published_display": "09 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70% - Anchored VWAP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZWx5NV9OT3hnZkxyWVlESXd6UHg5a0N6MjMzQ3NWSV9nbmVjdFFiRWhxY1U5MFZMT3QtT05sQ0RPN3RYU2ZOZDlFQVNRcDBaTW93Wm1ZOGR0c1lSQzdLUTNPc2Q0OHNjQjlLQVV3cTZwODFpVmNyQzhEZGtmN3dwczdNUUk0ZFJlYjhSejJ1eS1XQ1hLMjhqNC1UNkZNYnRUdk1RcW9LY2k?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences to Participate in Upcoming Conferences in June", "summary": "ProMIS Neurosciences Inc. announced its participation in several healthcare conferences in June 2026, including the Jefferies Global Healthcare Conference and BIO International Convention. CEO Neil Warma will discuss the company's EpiSelect\u2122 platform and its lead Alzheimer's dise", "url": "https://www.globenewswire.com/news-release/2026/05/28/3303024/0/en/promis-neurosciences-to-participate-in-upcoming-conferences-in-june.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T14:39:12", "published_display": "28 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s drug trial data from ProMIS expected in early Q3 2026", "summary": "ProMIS Neurosciences (Nasdaq: PMN) announced it will participate in several healthcare and biotech conferences in June 2026 to discuss its EpiSelect\u2122 platform and lead Alzheimer\u2019s candidate PMN310. The company expects to report blinded 6-month interim data from its PRECISE-AD Pha", "url": "https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-to-participate-in-upcoming-conferences-in-rji7xs0xf506.html", "source_name": "Stock Titan", "published_at": "2026-05-28T14:08:48", "published_display": "28 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan", "summary": "ProMIS Neurosciences shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the shares available for issuance by 900,000 Common Shares. The approval occurred at the company's 2026 annual meeting where shareholders also elected seven director no", "url": "https://www.stocktitan.net/sec-filings/PMN/8-k-pro-mis-neurosciences-inc-reports-material-event-c3e0f422e485.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:39:12", "published_display": "23 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike", "summary": "ProMIS Neurosciences Inc. CEO Neil K. Warma has been granted 160,000 stock options with an exercise price of $10.77 per share. These options, which expire on May 20, 2036, will vest ratably over four years, contingent on his continued service to the company. The grant is primaril", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-3f921c5df36c.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:09:40", "published_display": "23 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) director granted options on 16,500 shares", "summary": "ProMIS Neurosciences (PMN) director Eugene Williams was granted options for 16,500 common shares on May 20, 2026, as part of his compensation. The options include 11,000 shares vesting fully by May 20, 2027, and 5,500 shares with 25% vesting immediately, and the rest ratably over", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-57ba0bc422eb.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:09:39", "published_display": "23 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years", "summary": "ProMIS Neurosciences Inc. (PMN) has awarded its Chief Scientific Officer, Neil Cashman, 50,000 stock options. These options, with an exercise price of $10.77 per share and an expiration date of May 20, 2036, will vest ratably over four years, contingent on his continued service t", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-6226c35bbaf6.html", "source_name": "Stock Titan", "published_at": "2026-05-23T02:08:48", "published_display": "23 May 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price", "summary": "ProMIS Neurosciences Inc. director William W. Wyman was granted two stock option awards for a total of 16,500 common shares. These options have an exercise price of $10.77 per share and an expiration date of May 20, 2036. The vesting schedules differ for each grant, with one vest", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-6c1cb98f17e5.html", "source_name": "Stock Titan", "published_at": "2026-05-23T01:39:28", "published_display": "23 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/promis-neurosciences-announces-first-quarter-103000283.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T10:30:00+00:00", "published_display": "12 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PMN Stock Price and Chart \u2014 NASDAQ:PMN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBoUE55d1k2bkJuYUlTbjM0eUdmb2NuRE9MWE5QQTdQT2Nxd3BPNVFEa0RTTU1lUUl5c3E4MmtVQXFPSlNfZXJ0bVhyRkczZDcyZ2RQQ0ZrVDk2M0k?oc=5", "source_name": "TradingView", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer\u2019s trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOU184bkpET0M0T0t6MzItS01ITEpUcWVGdkU3dnYwdjlfM0hlZFkwQUVqLUVmd2kwMHhOd2JJZVZpMTFiSHFBeVVJM0dPSzNJOTBtaHRHTWdyYkx6cXY4enBjZ0EyUHUwSFV0bEJGLW11UjNzSm1FNnZKV1VobkJDZFpKVWFoNklJNzNaV3NoR2ViaTZkZndxM0VyQ01ueG1BN19MMkVWT1p3M28xTlVDeTJiZ3hLR1hHUzFBS21n?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Stock Fluctuates Amid Market Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPNFZlbVA0OVdhQkZ1NW1MRThDU082UTRtbjJ5cldTNmFTZXRUZUNUOWlsUnhWOFJoVWc4Q2F4S2c4bE81US1uSTlsUUNQY05IMlRHMDA5QkltbWJrc09FTlJnWVJSUWdWLWg2VjNJZEEwSUhLTVVEMU53MzF4cm81QklNTHNxUQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (NASDAQ:PMN) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Promis Neuroscie (PMN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFB3N3RNZmZkdGZjTzJmdGpsenhYNVE5cGFsa2ZiX2hLOXJDNkFQU0Fja1pCSTZZS3ZFYlZUa3J3dTFZQ05LY3kyeTY0NXJtZjhac3c?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:22:01+00:00", "published_display": "25 Apr 2025 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences director Shafmaster purchases $255,750 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVjhmOTYtczVISENuZ3NOZFp3MjNYRjRrMlU2RGFBT3VRSTg0MTd6NGRINzlscmtQMXZBUjA1cDhpaWZUYV9raDRQUWZIejEwcllqOFdKQkF3bXNvVDZuNURGRkJFdm1GMGVLUXVzSk41QmFHRjhaYVBBdUFFSm83aUc3bDJQaWJLN0t1NDg3eEdPY2FEMW5TTnIzV1pIVXRNamN0MWlKWkJsaVVTUkVYNWdhaEYtV2Q5dlZ3aHFYTGZzNlJZTXlZ?oc=5", "source_name": "Investing.com", "published_at": "2024-09-24T07:00:00+00:00", "published_display": "24 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)", "summary": "Guggenheim reiterated its \"Buy\" rating for ProMIS Neurosciences (PMN) with a $35.00 price target, following a previous \"Buy\" rating from Roth MKM. Despite a quarterly GAAP net loss of $8.24 million, corporate insider sentiment is positive, with increased insider buying, including", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3292705/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T11:41:29", "published_display": "15 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS reports PMN310 oligomer reduction at 29 days", "summary": "ProMIS Neurosciences reported that its drug candidate PMN310 demonstrated dose-dependent reductions in detectable amyloid-beta oligomers within cerebrospinal fluid three and 29 days after a single dose. This finding provides an exploratory signal that PMN310 reached and engaged i", "url": "https://grafa.com/en/news/united-states/promis-pmn310-amyloid-oligomer-reduction-29-days", "source_name": "grafa.com", "published_at": "2026-07-14T11:01:00", "published_display": "14 Jul 2026 11:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in Amyloid-Beta Oligomers", "summary": "ProMIS Neurosciences Inc. (PMN) announced promising results from its Phase 1a trial for the Alzheimer's drug candidate PMN310, showing a dose-dependent reduction in amyloid-beta oligomers. Despite strong financial health with no debt, the company faces profitability challenges, r", "url": "https://www.gurufocus.com/news/8957080/promis-neurosciences-pmn-reports-dosedependent-reduction-in-amyloidbeta-oligomers", "source_name": "GuruFocus", "published_at": "2026-07-14T10:40:52", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Reports Dose-Dependent Reduction of Amyloid-Beta Oligomers for PMN310 in Healthy Volunteers", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPc2haeVBieEdKTTZCaXpodnA2QnFValNfWDB4NlIwTlFMemJuRWNjbWlhSnZ6UkRjSlZScGg1M2puZy1BM1FJNmluZHc0MFg3alBtRFRVU3NOdXduN2h2RHA3VmRvazVSRU84cFp2UVZ2enptVlFQNHRIMldMQTRDMm1BemZNcWV3N1RnNjdLQnhhcVpURjVDanM3X28yWkd6eWhKdlBST1BNV2ZrNFZKZmxDSWdXVHQxWTBpUGVGZjBMcVNsZDlfbENYT1c5YlpmdUhJcGczVS1xZDJ5T3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T06:40:00+00:00", "published_display": "14 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026", "summary": "ProMIS Neurosciences announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer's drug candidate, PMN310, at AAIC 2026. The findings from a Phase 1a trial showed a reduction in oligomers in healthy volunteers' cerebrospinal fluid, indica", "url": "https://www.globenewswire.com/news-release/2026/07/14/3326583/0/en/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-target-engagement-by-pmn310-at-aaic-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T06:40:04", "published_display": "14 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid", "summary": "ProMIS Neurosciences announced that its Alzheimer's drug candidate, PMN310, demonstrated a dose-dependent reduction of amyloid-beta oligomers (A\u03b2O) in cerebrospinal fluid after a single dose in healthy volunteers. This finding, presented at AAIC 2026, represents a significant mil", "url": "https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-reports-first-human-evidence-of-amyloid-beta-4yt28payuim6.html", "source_name": "Stock Titan", "published_at": "2026-07-14T06:40:04", "published_display": "14 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc. Financial Statements \u2013 NASDAQ:PMN", "summary": "This page provides financial statement information for ProMIS Neurosciences Inc. (NASDAQ:PMN). Key facts like market capitalization, dividend yield, and P/E ratio are currently unavailable, and the company has no history of paying dividends. ProMIS Neurosciences Inc. focuses on d", "url": "https://www.tradingview.com/symbols/PMN/financials-overview/", "source_name": "TradingView", "published_at": "2026-07-10T04:10:07", "published_display": "10 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates ProMIS Neurosciences at Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cantor-fitzgerald-initiates-promis-neurosciences-100223010.html", "source_name": "MT Newswires", "published_at": "2026-06-30T10:02:23+00:00", "published_display": "30 Jun 2026 10:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbU42Z0xNV2pXQ0pXZEtJNWp6Mk85Nm0yQ2g4d3pCREdITkNLY0RTVVF6LUFUN1FydGcwb2xGai1FYXBycUZuZ3BaM0dBZXV1bEVtQVZoOU1iekVBRXRuZVNxRTBfMkxxNjEwWWtlb1NvTzcxbEk2ZGxLOXVTa0JndlJldm5oMTZVZmhNQzE4R0RYY3VGWExiUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "The article \"Price to sales forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN\" from TradingView appears to be a stub or a section of a larger financial data page for ProMIS Neurosciences Inc. (PMN). It focuses on the \"Price to sales forward\" metric, although no specific value is ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:34", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "This article provides a brief mention of the \"Enterprise value to revenue forward\" metric for ProMIS Neurosciences Inc. (NASDAQ:PMN). It appears to be a financial data point presented on TradingView, likely indicating a valuation ratio for the company. The content itself is very ", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:12:10", "published_display": "26 Jun 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN)", "summary": "This article provides an overview of ProMIS Neurosciences Inc. (NASDAQ:PMN) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial actuals and estimates for earnings and revenue, notes the company's next earn", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:12:10", "published_display": "25 Jun 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ProMIS Neurosciences Inc. \u2013 NASDAQ:PMN", "summary": "This article displays the \"Price to earnings forward\" metric for ProMIS Neurosciences Inc. (NASDAQ: PMN) on the TradingView platform. The content primarily features navigation elements and data source attributions, with the core financial data point itself being the main focus fo", "url": "https://www.tradingview.com/symbols/NASDAQ-PMN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:11:11", "published_display": "25 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18", "summary": "HC Wainwright & Co. has reiterated its \"Buy\" rating for ProMIS Neurosciences (PMN), maintaining a price target of $18.00. While the biotech company, which focuses on neurodegenerative disease therapies, has a strong financial balance sheet (rated 9/10), its GF Score of 32/100 sug", "url": "https://www.gurufocus.com/news/8929551/pmn-reiterated-by-hc-wainwright-co-price-target-maintained-at-18", "source_name": "GuruFocus", "published_at": "2026-06-24T12:40:46", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18", "summary": "H.C. Wainwright has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained its target price at $18. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72040789/hc-wainwright-maintains-promis-neurosciences-pmnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T07:41:15", "published_display": "24 Jun 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy", "summary": "H.C. Wainwright has reiterated its Buy rating and $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN), noting the stock's current value of $10.69 represents a significant upside to the target. The firm highlighted ProMIS Neurosciences' plans to develop a subcutaneous formul", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-promis-neurosciences-stock-rating-at-buy-93CH-4757907", "source_name": "Investing.com", "published_at": "2026-06-23T19:39:43", "published_display": "23 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ProMIS Neurosciences Inc (PMN), detailing its current price momentum score, support and resistance levels, and an evaluation based on various technical indicators and moving averages. According to the analysis, PMN is currently suitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/technical", "source_name": "TradingKey", "published_at": "2026-06-19T00:09:50", "published_display": "19 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ProMIS Neurosciences Inc (PMN), detailing its business segments, regional revenue, and profit contribution. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue data availab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:33", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of ProMIS Neurosciences Inc (PMN), listing major shareholders and their proportions, as well as a breakdown by shareholder type. It also provides institutional shareholding data from Q1 2023 to Q1 2026, showing changes in the number ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:33", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ProMIS Neurosciences Inc (PMN), highlighting its current earnings forecast score of 8.40 and an average price target of $112.50 from 5 analysts, with most recommending a \"Buy\" trend. It details the company's recent EPS performance, w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:08", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ProMIS Neurosciences Inc (PMN), noting its current valuation score of 6.70 within the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio, indicating a loss, and states that relevant data for P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pmn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T23:10:18", "published_display": "16 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-promis-135502622.html", "source_name": "Zacks", "published_at": "2026-06-12T13:55:02+00:00", "published_display": "12 Jun 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTEZnWmR3cXhHMjRyckJ5S3BpbkhSZFEtcHpLbTE5VGJrZEZJc05aaDM4SG5FRWhWS0xtbEM4cS03LWZHcDV1T1dwV1RFUGFYSTVkZjZLby1YMVp5elhBOTRfSENsUk1Pam5wZUtyRmNDLVRZT3F4N0pwVy1DWTRsbk8tc3I2UEhhbzdra3JFZmpzdGRFVnZibnNOOERZUU1zTGpJ?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and an $18.00 price target for ProMIS Neurosciences (NASDAQ:PMN). The company's stock is currently trading at $9.71, and InvestingPro analysis suggests it is undervalued. ProMIS Neurosciences is nearing key milestones for its Phase 1b t", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-buy-on-promis-neurosciences-stock-93CH-4681696", "source_name": "Investing.com Canada", "published_at": "2026-06-09T11:39:13", "published_display": "09 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70% - Anchored VWAP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZWx5NV9OT3hnZkxyWVlESXd6UHg5a0N6MjMzQ3NWSV9nbmVjdFFiRWhxY1U5MFZMT3QtT05sQ0RPN3RYU2ZOZDlFQVNRcDBaTW93Wm1ZOGR0c1lSQzdLUTNPc2Q0OHNjQjlLQVV3cTZwODFpVmNyQzhEZGtmN3dwczdNUUk0ZFJlYjhSejJ1eS1XQ1hLMjhqNC1UNkZNYnRUdk1RcW9LY2k?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences to Participate in Upcoming Conferences in June", "summary": "ProMIS Neurosciences Inc. announced its participation in several healthcare conferences in June 2026, including the Jefferies Global Healthcare Conference and BIO International Convention. CEO Neil Warma will discuss the company's EpiSelect\u2122 platform and its lead Alzheimer's dise", "url": "https://www.globenewswire.com/news-release/2026/05/28/3303024/0/en/promis-neurosciences-to-participate-in-upcoming-conferences-in-june.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T14:39:12", "published_display": "28 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alzheimer\u2019s drug trial data from ProMIS expected in early Q3 2026", "summary": "ProMIS Neurosciences (Nasdaq: PMN) announced it will participate in several healthcare and biotech conferences in June 2026 to discuss its EpiSelect\u2122 platform and lead Alzheimer\u2019s candidate PMN310. The company expects to report blinded 6-month interim data from its PRECISE-AD Pha", "url": "https://www.stocktitan.net/news/PMN/pro-mis-neurosciences-to-participate-in-upcoming-conferences-in-rji7xs0xf506.html", "source_name": "Stock Titan", "published_at": "2026-05-28T14:08:48", "published_display": "28 May 2026 14:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan", "summary": "ProMIS Neurosciences shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the shares available for issuance by 900,000 Common Shares. The approval occurred at the company's 2026 annual meeting where shareholders also elected seven director no", "url": "https://www.stocktitan.net/sec-filings/PMN/8-k-pro-mis-neurosciences-inc-reports-material-event-c3e0f422e485.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:39:12", "published_display": "23 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike", "summary": "ProMIS Neurosciences Inc. CEO Neil K. Warma has been granted 160,000 stock options with an exercise price of $10.77 per share. These options, which expire on May 20, 2036, will vest ratably over four years, contingent on his continued service to the company. The grant is primaril", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-3f921c5df36c.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:09:40", "published_display": "23 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) director granted options on 16,500 shares", "summary": "ProMIS Neurosciences (PMN) director Eugene Williams was granted options for 16,500 common shares on May 20, 2026, as part of his compensation. The options include 11,000 shares vesting fully by May 20, 2027, and 5,500 shares with 25% vesting immediately, and the rest ratably over", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-57ba0bc422eb.html", "source_name": "Stock Titan", "published_at": "2026-05-23T14:09:39", "published_display": "23 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years", "summary": "ProMIS Neurosciences Inc. (PMN) has awarded its Chief Scientific Officer, Neil Cashman, 50,000 stock options. These options, with an exercise price of $10.77 per share and an expiration date of May 20, 2036, will vest ratably over four years, contingent on his continued service t", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-6226c35bbaf6.html", "source_name": "Stock Titan", "published_at": "2026-05-23T02:08:48", "published_display": "23 May 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price", "summary": "ProMIS Neurosciences Inc. director William W. Wyman was granted two stock option awards for a total of 16,500 common shares. These options have an exercise price of $10.77 per share and an expiration date of May 20, 2036. The vesting schedules differ for each grant, with one vest", "url": "https://www.stocktitan.net/sec-filings/PMN/form-4-pro-mis-neurosciences-inc-insider-trading-activity-6c1cb98f17e5.html", "source_name": "Stock Titan", "published_at": "2026-05-23T01:39:28", "published_display": "23 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/promis-neurosciences-announces-first-quarter-103000283.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T10:30:00+00:00", "published_display": "12 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PMN Stock Price and Chart \u2014 NASDAQ:PMN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBoUE55d1k2bkJuYUlTbjM0eUdmb2NuRE9MWE5QQTdQT2Nxd3BPNVFEa0RTTU1lUUl5c3E4MmtVQXFPSlNfZXJ0bVhyRkczZDcyZ2RQQ0ZrVDk2M0k?oc=5", "source_name": "TradingView", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer\u2019s trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOU184bkpET0M0T0t6MzItS01ITEpUcWVGdkU3dnYwdjlfM0hlZFkwQUVqLUVmd2kwMHhOd2JJZVZpMTFiSHFBeVVJM0dPSzNJOTBtaHRHTWdyYkx6cXY4enBjZ0EyUHUwSFV0bEJGLW11UjNzSm1FNnZKV1VobkJDZFpKVWFoNklJNzNaV3NoR2ViaTZkZndxM0VyQ01ueG1BN19MMkVWT1p3M28xTlVDeTJiZ3hLR1hHUzFBS21n?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences Stock Fluctuates Amid Market Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPNFZlbVA0OVdhQkZ1NW1MRThDU082UTRtbjJ5cldTNmFTZXRUZUNUOWlsUnhWOFJoVWc4Q2F4S2c4bE81US1uSTlsUUNQY05IMlRHMDA5QkltbWJrc09FTlJnWVJSUWdWLWg2VjNJZEEwSUhLTVVEMU53MzF4cm81QklNTHNxUQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences (NASDAQ:PMN) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Promis Neuroscie (PMN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTFB3N3RNZmZkdGZjTzJmdGpsenhYNVE5cGFsa2ZiX2hLOXJDNkFQU0Fja1pCSTZZS3ZFYlZUa3J3dTFZQ05LY3kyeTY0NXJtZjhac3c?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:22:01+00:00", "published_display": "25 Apr 2025 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProMIS Neurosciences director Shafmaster purchases $255,750 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVjhmOTYtczVISENuZ3NOZFp3MjNYRjRrMlU2RGFBT3VRSTg0MTd6NGRINzlscmtQMXZBUjA1cDhpaWZUYV9raDRQUWZIejEwcllqOFdKQkF3bXNvVDZuNURGRkJFdm1GMGVLUXVzSk41QmFHRjhaYVBBdUFFSm83aUc3bDJQaWJLN0t1NDg3eEdPY2FEMW5TTnIzV1pIVXRNamN0MWlKWkJsaVVTUkVYNWdhaEYtV2Q5dlZ3aHFYTGZzNlJZTXlZ?oc=5", "source_name": "Investing.com", "published_at": "2024-09-24T07:00:00+00:00", "published_display": "24 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 47, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 31, "score": 55, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 14.25, "latest_week": "2026-07-10", "one_week_move": 6.7, "four_week_move": 37.7, "twelve_week_move": 23.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.085262, "market_dynamics_buy_signal": false, "relative_strength": -1.563301, "fair_value_gap": -48.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6534, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.7% over one week, +37.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 7}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.7% over one week, +37.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)"}], "updated_at": "2026-07-16T08:10:44.565382+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}